OBJECTIVE: To evaluate whether tocolysis with nifedipine can be omitted in women with symptoms of preterm labor, a shortened cervix and negative fetal fibronectin test.
INTRODUCTION
Preterm delivery is a common and severe complication of pregnancy. It occurs worldwide about 13 million times per year and is associated with morbidity and mortality. 1;2 In the developed world, most women with symptoms of preterm delivery before 34 weeks of gestation are hospitalized and treated with tocolytics and corticosteroids, but less than half of these women progress into imminent preterm delivery. 3 If we were able to identify women who do not benefit from treatment, we would be able to reduce maternal stress, side effects from treatment, and health care costs.
There are several tests to support the clinical evaluation of women with symptoms of preterm labor. Cervical length measurement can help in detecting women who will not progress into preterm delivery. If the cervix is 30 mm or longer, the risk of subsequent preterm delivery is estimated at less than 5%, a sound argument to withhold treatment. [4] [5] [6] [7] [8] On the other hand, a short cervix is not very specific for preterm birth, and treating all symptomatic women with a short cervix may lead to overtreatment.
Another method for evaluating women with suspected preterm labor is fetal fibronectin testing, based on a vaginal swab in which the concentration of the fetal fibronectin protein is measured. Cohort studies have shown that a negative fibronectin test is associated with a risk of subsequent preterm delivery of less than 5% in women with symptoms of preterm labor. 9;10 Unfortunately, it is unclear whether this is due to the fibronectin test result itself, or to the fact that tested women were treated with tocolytics. A randomized comparison showed that the use of the fibronectin test in clinical practice did not automatically reduce health care costs, possibly because physicians were not yet convinced that treatment could be omitted in case of a negative result. 11 To resolve this apparent contradiction between the results of cohort studies and findings from randomized trials we conducted a new randomized trial, to evaluate whether tocolysis can be omitted in women with symptoms preterm labor and a negative fibronectin test, without a considerable increase in premature births.
MATERIALS AND METHODS
We conducted a randomized controlled trial embedded in a prospective cohort study, designed to document the predictive performance of fibronectin testing and cervical length measurement. 12 The study had been approved by the ethical committee of the Amsterdam Medical Center before its initiation (trial number: NTR 1857) and ran within the Dutch Obstetric Consortium for perinatal research.
We recruited participants between December 2009 and August 2012 in all 10 Dutch perinatal centers with a tertiary referral function for high risk obstetrics. In the Netherlands, symptomatic women with a high risk of preterm delivery before 32 weeks are usually referred to one of these 10 perinatal centers.
At the time the study started, cervical length measurement was the standard of care in the Netherlands for risk stratification of women with complaints of preterm labor. To standardize the methods for cervical length measurement, all physicians were given a set of instructions [see Box 1] and a pocket card with illustrated examples of accurate cervical length measurements.
BOX 1 -Instructions to measure the cervical length
Instructions cervical length measurement 1. All cervical lengths must be measured vaginally.
2. Make sure the bladder is empty.
3. Place the ultrasound probe in the anterior fornix.
4. Visualize the endocervical mucosa, make sure both cervical lips are visualized the same size.
5. Observe the cervix for 2-3 minutes and measure the distance between the internal and external os at least three times with pauses in between.
6. A curved cervix must be measured in two steps.
7. The shortest cervical length counts.
Fetal fibronectin was not part of standard care in the Netherlands during the trial. Before the study started, physicians and midwifes were trained on how to collect a specimen. A specimen had to be collected prior to vaginal examination or cervical length measurement. In the participating hospitals the fetal fibronectin test (cutoff 50 ng/mL, 'Rapid fFN for the TLI IQ ® System' (Hologic, Inc.)) was done either at the central laboratory (4 centers) or as a point of care test at the obstetrical departments (6 centers). Training on how to analyse the fibronectin test was given; participation in training sessions was registered. All centers guaranteed the results of the fibronectin tests to be available within one hour. During the entire study period, a researcher was available by telephone 24 hours per day to answer questions regarding inclusion criteria, how to use the fetal fibronectin test and administration of study medication.
Participants
Pregnant women between 24-34 weeks with symptoms of preterm labor and intact membranes were eligible for inclusion in the cohort. They either presented as new cases of symptomatic preterm labor at one of the participating perinatal centers, or had been referred to these centers from secondary hospitals, by general practitioners, or by midwives. Women who had been treated with tocolytics within the previous seven days were excluded, with the exception of women who had received a single dose of tocolytic treatment for transport from a secondary hospital. Women with placenta praevia, contra-indications for tocolysis such as a lethal congenital abnormality, suspected intra-uterine infection, ruptured membranes or suspected fetal distress were also excluded.
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Eligible women were informed about the study by research nurses and midwifes of our nationwide clinical trials network, or by the gynecologist or resident on call. A fetal fibronectin test and a cervical length measurement were performed in all consenting women. Women within our cohort were eligible for the randomized trial if they had a negative fetal fibronectin test result and a cervical length between 10 and 30 mm. Exclusion criteria for randomisation were contra-indications for nifedipine, such as maternal cardiovascular disease or hypertension.
Randomisation
Eligible and consenting women were randomly allocated to oral nifedipine retard (20 mg four times per day, slow-release) or placebo immediately after the test results had become available. We used a blocked randomisation scheme, stratified for center, which was available by a secure website 24 hours per day. Each block consisted of four allocation codes. Study medication was given for 48 hours. Corticosteroids, antibiotics and maintenance tocolysis were given at the discretion of the attending physician. Progression of labor was monitored every 12 hours by clinical evaluation, and if needed by digital vaginal examination and/or cervical length measurement. In case of persistent symptoms of preterm labor, study medication could be increased up to a total dose of 120 mg nifedipine or placebo per day. In case of progression of labor under study medication to cervical dilation of 2 cm or beyond, study medication could be stopped and replaced by tocolytics according to the local protocol. Unblinding of study medication was allowed in case of suspected maternal or fetal side-effects of nifedipine. For this purpose, a 24-hour telephone service was provided.
If preterm delivery did not occur in the first 48 hours, further medical interventions and hospitalisation were at discretion of the attending physician. Second courses of corticosteroids, tocolytics and antibiotics could be given if deemed necessary.
Outcomes
The primary outcome was delivery within seven days. Secondary outcomes were preterm delivery before 34 and 37 weeks of gestation, gestational age at delivery, side-effects of nifedipine, and a composite adverse neonatal outcome. The composite adverse neonatal outcome consisted of neonatal death, chronic lung disease (in need of oxygen at 28 days after birth), intraventricular haemorrhage more than grade 2, periventricular leucomalacia more than grade 1, proven sepsis or necrotizing enterocolitis. Sepsis had to be proven by a positive blood culture. We separately assessed birth weight, Apgar score below 7 after five minutes, academia (cord arterial pH ≤ 7.05), infant respiratory distress syndrome and admission to a neonatal intensive care unit. In case of a twin pregnancy, an adverse neonatal outcome was considered to be present if at least one neonate met the definition of an adverse outcome.
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Statistical analysis
Analyses were according to the intention to treat principle. In the primary analysis, we calculated the difference in the proportion of women with delivery within seven days between the group of women allocated to nifedipine and the group allocated to placebo. The associated one-sided 95% confidence limit for the absolute risk difference was calculated. Differences in secondary outcome were assessed similarly. For continuous outcomes, two-sided Mann-Whitney U tests were performed. A Kaplan Meier analysis with a log rank test was used to compare time to delivery between groups.
We also evaluated the characteristics and outcomes of eligible non-randomized women. These women were treated according to the discretion of the responsible gynecologist. Within this group, we compared outcomes between women who were treated with tocolytics and those monitored expectantly, without tocolytics. All analyses were performed using SPSS software (version 19; IBM Chicago IL).
Sample size
The study was designed as a non-inferiority effectiveness trial. We anticipated that in our population of women with a cervical length of 10-30 mm, a negative fibronectin test and nifedipine treatment, 5% would deliver within seven days. We calculated we would need 220 women (110 per arm) to achieve 80% power with a one-side test to exclude an absolute increase in the proportion of deliveries within seven days of 7.5% or more in the placebo group, at a 5% significance level. Expecting 33% of evaluated women to be eligible for randomisation, we had to test fetal fibronectin test in at least 660 consenting women.
RESULTS
We studied 714 women with symptoms of preterm labor. Of these 172 had both a negative fibronectin test and a cervical length between 10 and 30 mm. Thirty-three of them (19%) declined study medication after having been informed about the results of the cervical length and fibronectin testing, another 22 (13%) women had a medical contra-indication, 17 (9.9%) women could not be randomized because the study medication had passed the expiration date, and 27 (16%) were not randomized for unknown reasons during busy shifts. In those cases treatment was given at the discretion of the attending physician. The remaining 73 women were randomly allocated to nifedipine (n=37) or placebo (n=36) [ Figure 1 ]. Due to the expiration date of the study medication in December 2011 and limited financial support, we were not able to extend recruitment to our targeted number of randomized women.
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FIGUREN ZIJN OOK OPGEMAAKT IN PROEFSCHRIFT JOLANDE VIS (CHAPTER 9). DIE ZIJN VAN BETERE KWALITEIT FIGURE 1 -Flow diagram
FIGURE 1 -Flow diagram FFN, fetal fibronectin test; CL, cervical length
Of the randomized women, 44 (60%) were nulliparous and 12 (16%) had a twin pregnancy. Before inclusion, 15 women (21%) had been transferred from a secondary hospital to a perinatal center, while 16 (22%) had been referred directly from a midwifery practice. There were 12 women (16%) who had been given a first dose of tocolytics before transport to a neonatal center, in most cases nifedipine capsules 2 x 10 mg (n=6, half-life 1-4 hours 13 ) or atosiban (n=4, half-life 12-24 minutes 14 ). At inclusion, median gestational age was 29+6 (IQR 26+5 to 31+6) weeks. The median cervical length was 22 mm (IQR 18 to 26) and 24 women (33%) had cervical dilatation. Most maternal basis characteristics were comparable between the nifedipine and placebo groups, though there were twice as many twin pregnancies and women with a previous preterm delivery in the nifedipine group, and three times as many women referred from a peripheral hospital [ Table 1 ]. 
Data are number of patients (%) or median (IQR). Data are at baseline unless otherwise indicated. *, lower, medium, and higher professional schools denote preparatory, intermediate, and higher vocational education, respectively; †, data are missing for some participants
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Four randomized women (5.5%) did not complete the full 48 hours of study medication. One woman allocated to nifedipine stopped medication after one tablet because of palpitations with diarrhoea, and abdominal cramps in combination with lactose intolerance. Another woman in the nifedipine group decided to withdraw from the study after three tablets because of severe headaches. Two women stopped using medication because of progression of labor after two and four tablets, respectively: one woman had been allocated to placebo and the other to nifedipine. Both women were treated with atosiban and nifedipine; one of them subsequently delivered. There was no unblinding. Corticosteroids were given to 55 women (75%); antibiotics to 16 (22%) [ Table 2 ]. 
Data are number of patients (%). †, data are missing for some participants
Primary outcome
Three women in the nifedipine group (8.1%), including one twin pregnancy, and one woman with a singleton pregnancy in the placebo group (2.8%) delivered within seven days. The absolute risk reduction by nifedipine compared to placebo was -5.3%, in favor of placebo. The one-sided 95% confidence limit of the absolute risk reduction extended to 4.7% in favor of nifedipine. Given the prespecified non-inferiority boundary of 7.5%, we can reject the null hypothesis that placebo is inferior to nifedipine (p=0.021) [ Figure 2 ].
Secondary outcomes
In the nifedipine group, six (16%) women delivered before 34 weeks of gestation versus one in the placebo group (2.8%) [ Table 3 ]. The median gestational age at delivery was 37+0 weeks (IQR 34+6 to 38+5) in the nifedipine group compared to 38+2 weeks (IQR 37+0 to 39+6) in the placebo group (p=0.008) [ Figure 3 ]. In the nifedipine group, three pregnancies (8.1%), including two twin pregnancies, had poor neonatal outcomes, and none in the placebo group. One intra-uterine death of a twin occurred 35 days after randomisation; the fetus had developed subcutaneous oedema. One neonatal death of a singleton pregnancy occurred 28 days after birth due to multi-system organ failure after necrotizing enterocolitis. Both neonates of a twin pregnancy developed bronchopulmonary dysplasia, of whom one was also diagnosed with necrotizing enterocolitis and sepsis [ Table 3 ]. 
FIGURE 2 -Interpretation of the absolute risk reduction within a one-sided inferiority effectiveness design
Women without a preterm delivery (%)
Time from assessment to preterm delivery, censored at 37 weeks of gestation (days) Placebo Nifedipine Placebo -censored Nifedipine -censored p=0.037 
FIGURE 3 -Time to preterm delivery in the nifedipine and placebo group, censored at 37 weeks of gestation
Data are number of patients (%) or median (IQR) unless otherwise indicated. ARR, absolute risk reduction by nifedipine compared to placebo in percentages; a negative ARR indicates that more events occurred in the nifedipine group; *, two-sided p-values are given for the Mann-Whitney U test; †, calculation based on the mean value per pregnancy in case of a multiple gestation. ‡, data are missing for some participants
Of the women treated with nifedipine, 15 (41%) reported side effects, compared to 17 (47%) in the placebo group. The most frequently reported side effects in both groups were headaches and warm flushes.
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Non-randomized eligible women
Follow-up was available for all 99 women with a negative fibronectin test and a cervical length between 10-30 mm who had not been randomized. Maternal characteristics of these eligible non-randomized women are summarized in Table 1 . Of these women, 59 (60%) were treated with tocolytics; 47 (80%) with nifedipine. The 40 others did not receive treatment. The median cervical length of the women treated with tocolytics was 20 mm (IQR 16 to 24) versus 25 mm (IQR 21 to 28) in the expectant monitoring group. The medical interventions in both groups can be found in Table 2 . In the non-randomized tocolytics group two women (3.4%) delivered within seven days, compared to none in the expectant monitoring group [ Table 4 ]. Ten women (17%) In the tocolytics group delivered before 34 weeks of gestation versus 6 (15%) in the monitoring group. Median gestational age at delivery was 37+2 weeks (IQR 35+3 to 38+5) in the tocolytics group and 37+3 weeks (IQR 36+1 to 39+2) in the expectant monitoring group.
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DISCUSSION
Main Findings
In this randomized study we found that placebo treatment is not inferior to tocolysis with nifedipine in women with symptoms of preterm labor, a shortened cervical length and negative fibronectin test result. The rate of preterm deliveries within 7 days was 5.3% lower in the placebo group; this difference did not exceed the prespecified non-inferiority margin. Secondary outcomes also favor refraining from treatment in these women. Women treated with nifedipine had a significant lower gestational age at delivery. All poor neonatal outcomes, low Apgar scores, and low fetal pH happened in the nifedipine group. Outcomes observed in non-randomized women treated with tocolytics were similar to those in the placebo group. We did not see more maternal side-effects in the nifedipine group.
Strengths and Limitations
Although our outcomes favor placebo over nifedipine, strong conclusions about the general effectiveness of nifedipine testing cannot yet be drawn. We have to bear in mind that this study is small and did not reach its targeted sample size, as we were included fewer women than anticipated due to limited financial resources, the expiration date of the study medication, and a high ratio of nonrandomizations among the eligible women. There were also at least twice at much twin pregnancies, women with a previous preterm delivery, and women referred from a peripheral hospital in the nifedipine group as compared to the placebo group. In addition, the women in this study population are at low risk for imminent preterm delivery, as shown by the negative fibronectin tests. To assess the effectiveness of nifedipine, a larger high risk population might be more informative.
Interpretation
As nifedipine has not been compared to placebo before, we cannot easily compare our results with those of other studies. 15 Yet, the surprising but significant disadvantages of nifedipine in this small study group show that evaluation of established therapies is necessary and worthwhile. We recommend that future studies evaluate the effectiveness of nifedipine in a higher risk population, preferably a placebo controlled setting. Of all eligible fibronectin negative women, only six (3.5%) delivered within 7 days. This confirms the potential of fibronectin testing for risk stratification in women with symptoms of preterm labor and short cervical length; it suggests that tocolytic treatment can be omitted in case of a negative fibronectin test. This implies that the vast majority of these women can be reassured and send home, which could save a lot of stress for these women and their families 66 | Chapter 4 and potentially lead to major cost reductions. As the proportion of fibronectin negative women who were treated with tocolytics in the non-randomized group was as high as 60%, there is still much to gain.
The majority of our study population had been referred to a perinatal center because of preterm labor complaints. In the Netherlands, most low risk pregnant women are under the care of a midwife. If there are any problems, such as preterm contractions, the midwife performs the first triage and decides whether a referral to a gynecologist is indicated. The gynecologist performs the second triage and decides who will be admitted. In general, only women who progress into labor before 32 weeks of gestation are transferred from a secondary hospital to a tertiary perinatal center. As this study was conducted in tertiary perinatal hospitals, many women in our population were preselected as being at very high risk for imminent preterm delivery. As the a-priori risk for preterm delivery might differ in other populations, this could influence the negative predictive value of the fibronectin test. In addition, introducing the fibronectin test in low risk populations could increase overtreatment in case of fibronectin positive results if women would otherwise have been discharged.
Whether fibronectin testing should become standard of care in women with symptoms of preterm labor, or be used only in addition to an (inconclusive) cervical length measurement, should be further evaluated. The APOSTEL-I cohort study will soon provide more information about the test characteristics of the cervical length measurement and the fibronectin test alone, combined and as a stepwise test strategy. Data from this cohort will also be used to evaluate cost-effectiveness of these strategies, providing us information about the optimal test strategy for women with symptomatic preterm labor.
CONCLUSION
In conclusion, the low risk of preterm delivery in fibronectin negative women and the demonstrated non-inferiority of placebo relative to nifedipine strongly suggest that expectant monitoring is the treatment of choice in fibronectin test negative women with symptoms of preterm labor and a shortened cervical length.
